S. 1067 · 118th Congress (2023–2025)
Ensuring Timely Access to Generics Act of 2023
This bill establishes additional requirements related to citizen petitions concerning applications for generic drug or biosimilar market approval. (Citizen petitions are petitions submitted by third parties requesting that the Food and Drug Administration (FDA) take certain actions, such as requiring additional warnings on a drug.)
Under the bill, the FDA may deny a citizen petition that (1) was submitted primarily to delay the approval of the relevant application, or (2) does not on its face raise valid scientific or regulatory issues. Currently, the FDA may deny a petition as an attempt at delay only if the petition meets both of these requirements.
The bill also expressly requires a third party, before filing a lawsuit to force the FDA to set aside or prevent market approval of a generic drug or biosimilar, to first file a citizen petition with the information and arguments that form the basis of the lawsuit. A citizen petition must be filed within 60 days of when the filer knew or reasonably should have known the information that forms the basis of the petition.
Show official title
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReported by committee
This bill’s path
This is S. 1067’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Jeanne Shaheen (D-NH)
- Cosponsors
5 cosponsors
5 original · 0 later
- Sen. Tammy Baldwin (D-WI)· Original · Mar 29, 2023
- Sen. Michael F. Bennet (D-CO)· Original · Mar 29, 2023
- Sen. Mike Braun (R-IN)· Original · Mar 29, 2023
- Sen. Susan M. Collins (R-ME)· Original · Mar 29, 2023
- Sen. Marco Rubio (R-FL)· Original · Mar 29, 2023
- Policy area
- Health
- Subjects
- Drug safety, medical device, and laboratory regulation
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Mar 29, 2023 – Jun 22, 2023
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Reported by committee → No further action before the 118th Congress ended.
Committees
- SenateHealth, Education, Labor, and PensionsReferred Mar 29, 2023 · Markup May 11, 2023 · Reported Jun 22, 2023
May 11, 2023 · Meeting
May 2, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Ensuring Timely Access to Generics Act of 2023
Display title, Short title · Introduced in Senate, Reported to Senate
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Official title · Introduced in Senate